Table 2.

Risk Factors Impacting Cardiotoxicity

	β	S.E.	z	P
(Intercept)	−9.086	0.160	−56.671	<0.001
Dose	0.016	<0.001	85.286	<0.001
Follow up (Years)	0.048	0.006	8.298	<0.001
Dexrazoxane	−2.734	0.067	−40.905	<0.001
Topoisomerase Inhibitor	−1.646	0.033	−50.399	<0.001
Antimetabolite	0.626	0.062	10.086	<0.001
Female (%)	−0.796	0.317	−2.509	0.012

Cumulative anthracycline dose, length of follow-up and use of concomitant antimetabolite chemotherapeutic agents were significantly and positively correlated with cardiotoxicity. Female gender, use of dexrazoxane as a cardiac stabilizer and additional chemotherapy with topoisomerase inhibitors had significant protective effects on cardiotoxicity.